Latest 5-HT3 antagonist Stories
LUGANO, Switzerland and SINGAPORE, February 9, 2015 /PRNewswire/ -- The exclusive agreement builds on our existing partnerships in the area of cancer supportive care across
LUGANO, Switzerland and MEXICO CITY, February 2, 2015 /PRNewswire/ -- The exclusive agreement strengthens the existing alliance between the companies in the area of supportive
LUGANO, Switzerland, January 12, 2015 /PRNewswire/ -- Helsinn Healthcare SA announces that it has entered into a settlement agreement with Sandoz Inc.
LUGANO, Switzerland, October 23, 2014 /PRNewswire/ -- ~ At a dose of 20 mug/kg, Palonosetron, administered as a singledose, is as effective as ondansetron 0.15 mg/kg given
-- First New Fixed Combination Targeting Two Critical Pathways Involved in CINV -- LUGANO, Switzerland and WOODCLIFF LAKE, N.J., Oct. 13, 2014 /PRNewswire/ -- Helsinn Group and Eisai Inc.
CAMBRIDGE, England, October 7, 2014 /PRNewswire/ -- Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting
LUGANO, Switzerland and TOKYO, July 17, 2014 /PRNewswire/ -- Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the
LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the
WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, June 26, 2014 /PRNewswire/ -- Eisai Inc.
- Withering but not falling off, as a blossom that persists on a twig after flowering.